C3 is a possible target in patients with geographic atrophy. What do the latest data from ARVO tell us about the safety and tolerability of NGM621, a drug aimed at that point in the complement cascade? David Eichenbaum, MD, sat down with New Retina Radio to review the results of a phase 1 study evaluating NGM621 in patients with geographic atrophy. 

Also, Amy Schefler, MD joined the show to review the design, methods, and rationale for the creation of the COOG2, or the second iteration of the Collaborative Ocular Oncology Group. How might the COOG help advance treatment for ocular cancer? 

This editorially independent podcast is supported with advertising.